Omni Bio Pharmaceutical Inc

Omni Bio Pharmaceutical — Biotech Showcase 2011

22 slides from Omni Bio Pharmaceutical's conference presentation, Jan 11, 2011

  1. Slide 1: Omni Bio Pharmaceutical, Inc - Biotech Showcase

    Slide 1: Omni Bio Pharmaceutical, Inc - Biotech Showcase

    January 11, 2011 OTCBB: OMBP Omni Bio Pharmaceutical, Inc Biotech Showcase San Francisco, CA

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements Except for the historical information contained herein, the matters discussed in this presentation are forward-looking statements. The forward-looking statements in this presentation are based on information available to us as of the date any such statements are made and w

  3. Slide 3: Investor Highlights

    Slide 3: Investor Highlights

    Investor Highlights 3 IP Distribution Acceptance Innovation Broad intellectual property position in major markets - - Diabetes, influenza, transplant rejection, biohazards FDA approved pharmaceutical applied to new and large markets Outsourced business model requiring low overhead Capital requiremen

  4. Slide 4: Mission

    Slide 4: Mission

    Mission 4 Applying approved and safe products for the treatment of immunological conditions such as Type 1 and 2 diabetes, acute or chronic transplant rejection and drug resistant bacterial and viral infection Bacterial disorders Viral disorders Graft vs. host disease and transplant rejection Type 1

  5. Slide 5: The Opportunity

    Slide 5: The Opportunity

    The Opportunity 5 When How What To develop, patent, and commercialize previously approved (FDA) drugs in new patented indications with large market opportunities. An existing FDA approval for an existing drug means there are limited safety issues and a significantly reduced time to market for new in

  6. Slide 6: The Opportunity: Alpha-1-Antitrypsin (AAT)

    Slide 6: The Opportunity: Alpha-1-Antitrypsin (AAT)

    The Opportunity: Alpha-1-Antitrypsin (AAT) 6 Core Technology Advantages Anti-migratory Anti-complement Prevents maturation of antigen presentation Induces T-regulatory cells Inhibits responses to inflammatory cytokine Increases production of anti-inflammatory molecules Inhibits destructive enzymes s

  7. Slide 7: Target Populations

    Slide 7: Target Populations

    2M in US including adults 15-18,000 Type 1 juvenile diabetics diagnosed in US each year (40- 50/day) No alternative to insulin therapy 50,000 pre-Type 1 diabetics may benefit 24M in US Treatment of patients failing current therapy and/or high risk of cardiovascular complications is approximately 2.4

  8. Slide 8: IP Portfolio

    Slide 8: IP Portfolio

    IP Portfolio 8 Licensee of three patent portfolios from the University of Colorado-Denver comprising 3 issued and 19 filed patents Two issued patents and additional patent applications for the treatment of viral diseases including Influenza and HIV-1 Patent applications for the treatment of graft vs

  9. Slide 9: Sponsored Research & License Agreements

    Slide 9: Sponsored Research & License Agreements

    Composition of matter and methods of use for AAT-based treatment of: Sub-license components of the IP portfolio to one or more producers of AAT, many of whom are major pharmaceutical companies An affiliate of the University of Colorado owns approximately 5% of Omni's common stock 9 Type 1 and Type 2

  10. Slide 10: Research & Development Pipeline

    Slide 10: Research & Development Pipeline

    10 Research & Development Pipeline Diabetes Flu Tuberculosis Transplant Rejection Anthrax AAT Laboratory In-VitroProof-of-Concept Studies Proof-of-ConceptAnimal Studies FDA Approved Human Clinical Trial (IND)

  11. Slide 11: FDA Approved Human Clinical Trial

    Slide 11: FDA Approved Human Clinical Trial

    FDA Approved Human Clinical Trial Initial patients have been infused in Phase 1/2 human clinical trial of AAT in recently diagnosed Type 1 diabetics Preventing the destruction of insulin-producing islet (beta) cells Barbara Davis Center for Childhood Diabetes at the University of Colorado Hospital,

  12. Slide 12: The AAT Impact on Human Islets

    Slide 12: The AAT Impact on Human Islets

    12 Presence of IL-1b/IFNg + Vehicle Presence of IL-1b/IFNg + AAT r Human Islets: Effect of cytokine induced toxicity and protection by AAT The AAT Impact on Human Islets Disintegrating, dying islets, as takes place in vivo by immune attack Intact, living islets protected by AAT during an immune atta

  13. Slide 13: Influenza

    Slide 13: Influenza

    Influenza 13 In the U.S. each year: - - 10-20% of population infected (30-60 million people) Children and the elderly are at risk groups 114,000 hospitalizations - - 36,000 deaths - - Economic burden= $3-15 billion

  14. Slide 14: AAT Inhibits Flu Production in Infected Cells

    Slide 14: AAT Inhibits Flu Production in Infected Cells

    100% 80% 60% 40% 20% AAT Inhibits Flu Production in Infected Cells 14

  15. Slide 15: AAT: Protects Cells from Flu Infection

    Slide 15: AAT: Protects Cells from Flu Infection

    Flu alone Flu + AAT 15 AAT: Protects Cells from Flu Infection

  16. Slide 16: AAT Impact on Influenza

    Slide 16: AAT Impact on Influenza

    16 AAT Impact on Influenza Both a treatment and prophylactic product Potentially broad spectrum treatment for influenza including "bird Flu," "swine Flu (H1N1)," and "weaponized" Flu Impervious to mutation-induced resistance Compatible with existing Flu treatments and immunization Inhaled delivery p

  17. Slide 17: Balance Sheet

    Slide 17: Balance Sheet

    17 Balance Sheet ($ in Millions) Sept. 30, 2010 March 31, 2010 Cash 0.7 1.8 Current Assets 1.2 1.8 Total Assets 1.2 1.9 Current Liabilities 0.1 0.2 Total Stockholders' Equity 1.1 1.7 Total Liabilities and Stockholders' Equity 1.2 1.9

  18. Slide 18: About Omni Bio

    Slide 18: About Omni Bio

    18 OTC BB: OMBP Fiscal year end: March 31 Outstanding shares at Dec 31, 2010: 29.0 million Common Stock & Equivs. O/S at Dec 31, 2010: 39.6 million Closing Stock price at January 6, 2011: $4.00 52 week range: $2.99 - $12.00 About Omni Bio

  19. Slide 19: Management

    Slide 19: Management

    Management Chief Executive Officer-Charles A. Dinarello, MD - - Member of the National Academy of Sciences - - World's fourth most-cited scientist for 20 years (1982-2003 Institute for Scientific Information ) - - Numerous international awards : - - 2008 Sheik Hamdan Prize (United Arab Emirates) - -

  20. Slide 20: Principal Investigator at the University of Colorado-Denver

    Slide 20: Principal Investigator at the University of Colorado-Denver

    Principal Investigator at the University of Colorado-Denver, Anschutz Medical Campus Dr. Leland Shapiro, MD, FACP -Associate Professor of Medicine -Certified by American Board of Internal Medicine -Broadly Published Researcher on alternative uses of Alpha-1 antitrypsin 20

  21. Slide 21: Investment Opportunity

    Slide 21: Investment Opportunity

    Investment Opportunity Investment Opportunity World-class scientific leadership and strong management team Proven pharmaceutical applied to new and larger markets Phase 1/2 human clinical trial for Type 1 diabetes now in progress .. Three patents issued and 19 patents pending Sponsored research and

  22. Slide 22: Thank you for your interest

    Slide 22: Thank you for your interest

    Thank you for your interest Thank you for your interest 22

Source: SEC EDGAR · 8-K filed Jan 11, 2011

More decks from Omni Bio Pharmaceutical Inc